Decibel Therapeutics Company

Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatics analyses, precision gene therapy technology and our expertise in inner ear biology. We are leveraging our platform to advance our pipeline of preclinical gene therapy programs that are designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders.

Estimated Revenue: $10M to $50M
Funding Status: IPO
Headquarters: Cambridge, Massachusetts, United States
Total Funding: 189.2M
Last Funding Date: 2020
Investors Number: 16
Number Of Exists: 51-100
Founded Date: 2015
Technology: Other
Industry: Biotechnology, Gene therapy, Medical Device, Therapeutics
Last Funding Type: Series D
Investor Type: IPO
Employee Number: 51-100